Cybrexa Therapeutics has appointed Dr. Michael N. Needle as Chief Medical Officer. A board-certified hematologist/oncologist, Dr. Needle will be responsible for overseeing and strategizing the continued development of Cybrexa’s advancing pipeline.
The Company recently presented positive findings from its first-in-human study of lead candidate, CBX-12 (alphalex™-exatecan).